PathAI Extends its Multi-Year Collaboration with BMS to Develop Therapies Using AI
Shots:
- The companies focus to expand the use of AI for the development of therapies through translational research, clinical trials & diagnostic across the areas of oncology, fibrosis, and immunology
- The companies also use AI pathology models to advance patient segmentation in clinical trials across multiple disease indications & will also develop AI-powered diagnostics measuring CD8 T-cell infiltration across oncology disease areas
- The extended collaboration was based on the 2016 collaboration & has recently presented the results in the Journal of Modern Pathology that compares the use of AI-powered algorithms against manual IHC scoring PD-L1 expression related to outcomes across multiple cancer types in multiple trials
Ref: Businesswire | Image: BMS
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
